Insulin efsitora alfa - Eli Lilly and Company
Alternative Names: Basal Insulin-FC; Insulin efsitora alfa-gobe; LY-3209590; OnswikLatest Information Update: 06 Oct 2026
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- Class Antihyperglycaemics; Immunoglobulin Fc fragments; Insulins; Pancreatic hormones; Recombinant fusion proteins
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Type 2 diabetes mellitus
- Phase III Type 1 diabetes mellitus